临床试验/2025-523804-62-00

2025-523804-62-00招募中3 期

Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).

Novo Nordisk A/S93 个研究点分布在 8 个国家目标入组 325 人开始时间: 2026年4月21日最近更新: 2026年8月27日

适应症

干预措施

试验速览

阶段: 3 期
状态: 招募中
发起方: Novo Nordisk A/S
入组人数: 325
试验地点: 93

研究概览入排标准研究组 & 干预措施研究者研究点记录与标识符相似试验

研究概览

简要总结

To confirm superiority of NNC0487-0111 CCI versus placebo on change in body weight in participants with obesity

入排标准

年龄范围: 18 years 至 64 years（18-64 Years）
接受健康志愿者: 否

入选标准

•Male or female (sex at birth).
•Age between 18 CCI years CCI at the time of signing informed consent.
•Body Mass Index (BMI) ≥ CCI kg/m

排除标准

•Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.
•History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
•Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues within CCI before screening.

研究组 & 干预措施

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: zenagamtide B 10176 (Drug)

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: NNC0487-0111 B 10145 (Drug)

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: NNC0487-0111 B 10144 (Drug)

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: NNC0487-0111 B 10142 (Drug)

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: NNC0487-0111 B 10143 (Drug)

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: NNC0487-0111 B 10141 (Drug)

NNC0487-0111 B 10141, zenagamtide B 10176, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10143

Test

干预措施: NNC0487-0111 B 10146 (Drug)

Placebo

干预措施: Placebo (Drug)

研究者

发起方

Novo Nordisk A/S

申办方类型

Pharmaceutical company

责任方

Principal Investigator

主要研究者

EU Submission Hub

Scientific

Novo Nordisk A/S

研究点 (93)

Loading locations...

相似试验

招募中

3 期

AMAZE 6: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose weight and reduce painOverweight or obesity, and knee osteoarthritis

2024-520445-23-00Novo Nordisk A/S220

招募中

3 期

AMAZE 3: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoeaOverweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

2024-520442-36-00Novo Nordisk A/S125

招募中

3 期

AMAZE 5: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose weight and reduce painOverweight or obesity, and knee osteoarthritis

2024-520444-42-00Novo Nordisk A/S220

招募中

3 期

AMAZE 4: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and obstructive sleep apnoea treated with positive airway pressure lose weight and improve sleep apnoeaOverweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

2024-520443-16-00Novo Nordisk A/S115

已完成

3 期

一项旨在检验 BI 456906 是否有助于超重或肥胖中国患者减重的研究超重或肥胖

CTR20234328——/ 勃林格殷格翰(中国)投资有限公司